These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 26625717)

  • 1. PEGylated siRNA lipoplexes for silencing of BLIMP-1 in Primary Effusion Lymphoma: In vitro evidences of antitumoral activity.
    Belletti D; Tosi G; Forni F; Lagreca I; Barozzi P; Pederzoli F; Vandelli MA; Riva G; Luppi M; Ruozi B
    Eur J Pharm Biopharm; 2016 Feb; 99():7-17. PubMed ID: 26625717
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PEGylation of lipoplexes: The right balance between cytotoxicity and siRNA effectiveness.
    Lechanteur A; Furst T; Evrard B; Delvenne P; Hubert P; Piel G
    Eur J Pharm Sci; 2016 Oct; 93():493-503. PubMed ID: 27593989
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Small interfering RNA delivery into the liver by cationic cholesterol derivative-based liposomes.
    Hattori Y; Machida Y; Honda M; Takeuchi N; Yoshiike Y; Ohno H; Onishi H
    J Liposome Res; 2017 Dec; 27(4):264-273. PubMed ID: 27345333
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhanced endosomal/lysosomal escape by distearoyl phosphoethanolamine-polycarboxybetaine lipid for systemic delivery of siRNA.
    Li Y; Cheng Q; Jiang Q; Huang Y; Liu H; Zhao Y; Cao W; Ma G; Dai F; Liang X; Liang Z; Zhang X
    J Control Release; 2014 Feb; 176():104-14. PubMed ID: 24365128
    [TBL] [Abstract][Full Text] [Related]  

  • 5. siRNA delivery by a transferrin-associated lipid-based vector: a non-viral strategy to mediate gene silencing.
    Cardoso AL; Simões S; de Almeida LP; Pelisek J; Culmsee C; Wagner E; Pedroso de Lima MC
    J Gene Med; 2007 Mar; 9(3):170-83. PubMed ID: 17351968
    [TBL] [Abstract][Full Text] [Related]  

  • 6. siRNA delivery to lung-metastasized tumor by systemic injection with cationic liposomes.
    Hattori Y; Nakamura A; Arai S; Kawano K; Maitani Y; Yonemochi E
    J Liposome Res; 2015; 25(4):279-86. PubMed ID: 25543847
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Zwitterionic poly(carboxybetaine)-based cationic liposomes for effective delivery of small interfering RNA therapeutics without accelerated blood clearance phenomenon.
    Li Y; Liu R; Shi Y; Zhang Z; Zhang X
    Theranostics; 2015; 5(6):583-96. PubMed ID: 25825598
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of PEG anchors in PEGylated siRNA lipoplexes on in vitro gene‑silencing effects and siRNA biodistribution in mice.
    Hattori Y; Tamaki K; Sakasai S; Ozaki KI; Onishi H
    Mol Med Rep; 2020 Nov; 22(5):4183-4196. PubMed ID: 33000194
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development and characterization of siRNA lipoplexes: Effect of different lipids, in vitro evaluation in cancerous cell lines and in vivo toxicity study.
    Khatri N; Baradia D; Vhora I; Rathi M; Misra A
    AAPS PharmSciTech; 2014 Dec; 15(6):1630-43. PubMed ID: 25145330
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Post-pegylated lipoplexes are promising vehicles for gene delivery in RPE cells.
    Peeters L; Sanders NN; Jones A; Demeester J; De Smedt SC
    J Control Release; 2007 Aug; 121(3):208-17. PubMed ID: 17630013
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficient in vitro gene therapy with PEG siRNA lipid nanocapsules for passive targeting strategy in melanoma.
    Resnier P; LeQuinio P; Lautram N; André E; Gaillard C; Bastiat G; Benoit JP; Passirani C
    Biotechnol J; 2014 Nov; 9(11):1389-401. PubMed ID: 25262914
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cationic Liposomes Carrying HPV16 E6-siRNA Inhibit the Proliferation, Migration, and Invasion of Cervical Cancer Cells.
    Sánchez-Meza LV; Bello-Rios C; Eloy JO; Gómez-Gómez Y; Leyva-Vázquez MA; Petrilli R; Bernad-Bernad MJ; Lagunas-Martínez A; Medina LA; Serrano-Bello J; Organista-Nava J; Illades-Aguiar B
    Pharmaceutics; 2024 Jun; 16(7):. PubMed ID: 39065577
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stealth monoolein-based nanocarriers for delivery of siRNA to cancer cells.
    Oliveira AC; Raemdonck K; Martens T; Rombouts K; Simón-Vázquez R; Botelho C; Lopes I; Lúcio M; González-Fernández Á; Real Oliveira ME; Gomes AC; Braeckmans K
    Acta Biomater; 2015 Oct; 25():216-29. PubMed ID: 26225736
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preparation of PEGylated cationic nanoliposome-siRNA complexes for cancer therapy.
    Haghiralsadat F; Amoabediny G; Naderinezhad S; Forouzanfar T; Helder MN; Zandieh-Doulabi B
    Artif Cells Nanomed Biotechnol; 2018; 46(sup1):684-692. PubMed ID: 29475393
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tf-lipoplexes for neuronal siRNA delivery: a promising system to mediate gene silencing in the CNS.
    Cardoso AL; Simões S; de Almeida LP; Plesnila N; Pedroso de Lima MC; Wagner E; Culmsee C
    J Control Release; 2008 Dec; 132(2):113-23. PubMed ID: 18796321
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of PEG anchor in PEGylation of folate-modified cationic liposomes with PEG-derivatives on systemic siRNA delivery into the Tumor.
    Tang M; Sakasai S; Onishi H; Kawano K; Hattori Y
    J Drug Target; 2023 Jan; 31(1):74-88. PubMed ID: 35864749
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhanced siRNA delivery using cationic liposomes with new polyarginine-conjugated PEG-lipid.
    Kim HK; Davaa E; Myung CS; Park JS
    Int J Pharm; 2010 Jun; 392(1-2):141-7. PubMed ID: 20347025
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PEGylated DC-Chol/DOPE cationic liposomes containing KSP siRNA as a systemic siRNA delivery Carrier for ovarian cancer therapy.
    Lee J; Ahn HJ
    Biochem Biophys Res Commun; 2018 Sep; 503(3):1716-1722. PubMed ID: 30049442
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Poly(vinyl pyrrolidone) derivatives as PEG alternatives for stealth, non-toxic and less immunogenic siRNA-containing lipoplex delivery.
    Berger M; Toussaint F; Djemaa SB; Laloy J; Pendeville H; Evrard B; Jerôme C; Lechanteur A; Mottet D; Debuigne A; Piel G
    J Control Release; 2023 Sep; 361():87-101. PubMed ID: 37482343
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transfection efficacy and drug release depends upon the PEG derivative in cationic lipoplexes: Evaluation in 3D in vitro model and in vivo.
    A M G; O O K; A S N; L I V; V A S; L A K; E A E; V V S; U A B; Yu L S; N E S; M R K; E M
    J Biomed Mater Res B Appl Biomater; 2023 Sep; 111(9):1614-1628. PubMed ID: 37132593
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.